Although roflumilast is known to show a body weight lowering effect in the clinical setting, treatment with the tested PDE4 inhibitors has a beneficial effect on weight loss in our fibrosis model compared to nintedanib and, less so, pirfenidone. This evidence concerns the gene PDE4A and fibrosis.